Abstract
Historically, the central nervous system (CNS) was considered an immune-privileged organ. However, recent studies have shown that the immune system plays a significant role in the CNS. Thus, there is renewed interest in applying cancer immunotherapy to CNS malignancies with the hope of generating a robust anti-tumor immune response and creating long-lasting immunity in patients. There has been some work with non-specific immunotherapy such as IL-2 for brain metastasis. Unfortunately, the results from non-specific immunotherapy studies were lackluster, so the focus has shifted to more specific CNS immunotherapies including cancer vaccines, immune checkpoint inhibitors, oncolytic virus therapy, and chimeric antigen receptor (CAR) T cell therapy. With respect to cancer vaccines, rindopepimut has been well-studied in glioblastoma (GBM) patients with the EGFRvIII mutation, with early results from phase II trials showing possible efficacy in carefully selected GBM patients. Other antigen-specific CNS tumor vaccines are still in the early stages. Immune checkpoint inhibitors are amongst the most promising and widely studied CNS immunotherapy strategies. Anti-PD-1 showed promising results in many non-CNS solid tumors, however, results from early clinical trials show poor efficacy for anti-PD-1 in GBM patients. Anti-PD-1 is also under investigation for CNS metastasis and showed some efficacy in non-small cell lung cancer and renal cell carcinoma patients. Anti-PD-1 is under early stage investigation for other CNS tumors such as chordoma. Oncolytic virus therapy is the strategy of infecting tumor cells with a virus that in turn triggers an innate immune response leading to tumor cell lysis. Oncolytic viruses currently under investigation include several adenovirus-based therapies and a herpes simplex virus-based therapy. Phase I studies have demonstrated the safety of oncolytic virus therapies in GBM patients. Current studies are evaluating the efficacy of these therapies both alone and in combination with other immunotherapy approaches such as checkpoint inhibition in patients with CNS tumors. CAR T cell therapy is a newer immunotherapy approach. CAR T cell therapies, directed against EGFRvIII mutation and HER-2 mutation, demonstrate an acceptable safety profile, although there is no conclusive evidence of the survival benefit of these therapies in early trials. Studies are currently underway to determine optimal tumor-specific antigen selection and modality of administration for CAR T cell therapy. Overall, the prognosis is generally poor for patients with CNS malignancies. The promising results of cancer immunotherapy for non-CNS tumors have created significant interest in applying these therapies for CNS malignancies. Preliminary results have not demonstrated robust efficacy for CNS immunotherapy. However, it is important to keep in mind that the field is still in its infancy and many clinical trials are still early-phase. Several, clinical trials are currently underway to further explore the role of immunotherapy for CNS malignancies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ahmed N et al (2017) HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol 3:1094–1101. https://doi.org/10.1001/jamaoncol.2017.0184
Aspelund A et al (2015) A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med 212:991–999
Banks WA (2015) The blood-brain barrier in neuroimmunology: tales of separation and assimilation. Brain Behav Immun 44:1–8
Barker CF, Billingham R (1978) Immunologically privileged sites. Adv Immunol 25:1–54
Black KL, Ciacci JD, Ammirati M, Selch MT, Becker DP (1993) Clinical trial of Serratia marcescens extract and radiation therapy in patients with malignant astrocytoma. J Clin Oncol: Off J Am Soc Clin Oncol 11:1746–1750. https://doi.org/10.1200/jco.1993.11.9.1746
Bloch O et al (2014) Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol 16:274–279. https://doi.org/10.1093/neuonc/not203
Bloch O et al (2017) Autologous heat shock protein peptide vaccination for newly diagnosed glioblastoma: impact of peripheral PD-L1 expression on response to therapy. Clin Cancer Res: Off J Am Assoc Cancer Res 23:3575–3584. https://doi.org/10.1158/1078-0432.CCR-16-1369
Bouffet E et al (2016) Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34:2206–2211. https://doi.org/10.1200/JCO.2016.66.6552
Bracarda S et al (2018) Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program. Futur Oncol (Lond, Engl) 14:1347–1354. https://doi.org/10.2217/fon-2017-0570
Brown CE et al (2016) Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 375:2561–2569. https://doi.org/10.1056/NEJMoa1610497
Chandar A et al (2015) Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma. J Immunother Cancer 3:P129–P129. https://doi.org/10.1186/2051-1426-3-S2-P129
Chiocca EA et al (2004) A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther: J Am Soc Gene Ther 10:958–966. https://doi.org/10.1016/j.ymthe.2004.07.021
Cloughesy TF et al. (2018) Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro Oncol 20:1383–1392. https://doi.org/10.1093/neuonc/noy075
Cloughesy TF et al. (2019) Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 25:477–486. https://doi.org/10.1038/s41591-018-0337-7
Crino L et al (2019) Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer (Amst, Neth) 129:35–40. https://doi.org/10.1016/j.lungcan.2018.12.025
Desjardins A et al (2018) Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 379:150–161. https://doi.org/10.1056/NEJMoa1716435
Di Giacomo AM et al (2012) Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 13:879–886. https://doi.org/10.1016/s1470-2045(12)70324-8
Di Giacomo AM et al. (2015a) A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial. J Clin Oncol 33:TPS9090–TPS9090. https://doi.org/10.1200/jco.2015a.33.15_suppl.tps9090
Di Giacomo AM et al (2015b) Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Ann Oncol: Off J Eur Soc Med Oncol 26:798–803. https://doi.org/10.1093/annonc/mdu577
Du Z et al (2015) Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget 6:4704–4716. https://doi.org/10.18632/oncotarget.3082
Emamekhoo H et al (2019) Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920. J Clin Oncol 37:4517–4517. https://doi.org/10.1200/JCO.2019.37.15_suppl.4517
Fecci PE et al (2007) Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res: Off J Am Assoc Cancer Res 13:2158–2167. https://doi.org/10.1158/1078-0432.ccr-06-2070
Feng Y et al (2015) Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma. Oncotarget 6:11139–11149. https://doi.org/10.18632/oncotarget.3576
Finney HM, Akbar AN, Lawson AD (2004) Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 172:104–113. https://doi.org/10.4049/jimmunol.172.1.104
Flippot R et al (2019) Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study. J Clin Oncol: Off J Am Soc Clin Oncol 37:2008–2016. https://doi.org/10.1200/jco.18.02218
Forrester JV, McMenamin PG, Dando SJ (2018) CNS infection and immune privilege. Nat Rev Neurosci 19:655–671
Freeman AI et al (2006) Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther: J Am Soc Gene Ther 13:221–228. https://doi.org/10.1016/j.ymthe.2005.08.016
Galea I, Bechmann I, Perry VH (2007) What is immune privilege (not)? Trends Immunol 28:12–18
Goldberg SB et al. (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial Lancet Oncol 17:976–983. https://doi.org/10.1016/s1470-2045(16)30053-5
Goldman JW et al (2016) Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets). J Clin Oncol 34:9038–9038. https://doi.org/10.1200/JCO.2016.34.15_suppl.9038
Gorbachev AV et al (2007) CXC chemokine ligand 9/monokine induced by IFN-γ production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J Immunol 178:2278–2286
Guirguis LM, Yang JC, White DE, Steinberg SM, Liewehr DJ, Rosenberg SA, Schwartzentruber DJ (2002) Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother (Hagerstown, Md: 1997) 25:82–87
Han SJ et al (2016) Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. J Neurooncol 130:543–552. https://doi.org/10.1007/s11060-016-2256-0
Harris-Bookman S et al (2018) Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma. Int J Cancer 143:3201–3208. https://doi.org/10.1002/ijc.31661
Jena B, Dotti G, Cooper LJ (2010) Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116:1035–1044. https://doi.org/10.1182/blood-2010-01-043737
Killela PJ et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110:6021–6026. https://doi.org/10.1073/pnas.1303607110
Klein RS et al (2004) IFN-inducible protein 10/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis. J Immunol 172:550–559
Kluger HM et al (2019) Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. J Clin Oncol: Off J Am Soc Clin Oncol 37:52–60. https://doi.org/10.1200/jco.18.00204
Lim M et al. (2017) 325ONivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM). Ann Oncol 28. https://doi.org/10.1093/annonc/mdx366
Long GV et al (2018) Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 19:672–681. https://doi.org/10.1016/s1470-2045(18)30139-6
Louveau A et al (2015) Structural and functional features of central nervous system lymphatic vessels. Nature 523:337–341
Mahaley MS Jr et al (1983) Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: a pilot study. J Neurosurg 59:201–207. https://doi.org/10.3171/jns.1983.59.2.0201
Margolin K et al (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13:459–465. https://doi.org/10.1016/s1470-2045(12)70090-6
Markert JM et al (2014) A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther: J Am Soc Gene Ther 22:1048–1055. https://doi.org/10.1038/mt.2014.22
Mathios D et al (2015) PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. J Neurooncol 121:251–259. https://doi.org/10.1007/s11060-014-1637-5
Mayo L, Quintana FJ, Weiner HL (2012) The innate immune system in demyelinating disease. Immunol Rev 248:170–187
Medawar PB (1948) Immunity to homologous grafted skin. III. The fate of skin homographs transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 29:58
Motzer RJ et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813. https://doi.org/10.1056/NEJMoa1510665
Omuro A et al (2018) Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol 20:674–686. https://doi.org/10.1093/neuonc/nox208
O'Rourke DM et al. (2017) A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 9. https://doi.org/10.1126/scitranslmed.aaa0984
Parakh S et al (2017) Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. Br J Cancer 116:1558–1563. https://doi.org/10.1038/bjc.2017.142
Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264. https://doi.org/10.1038/nrc3239
Paz-Ares L et al. (2015) Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). J Clin Oncol 33:LBA109–LBA109. https://doi.org/10.1200/jco.2015.33.18_suppl.lba109
Perry VH (1998) A revised view of the central nervous system microenvironment and major histocompatibility complex class II antigen presentation. J Neuroimmunol 90:113–121
Peruzzi P, Chiocca EA (2018) Viruses in cancer therapy - from benchwarmers to quarterbacks. Nat Rev Clin Oncol 15:657–658. https://doi.org/10.1038/s41571-018-0077-0
Phuong LK et al (2003) Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Can Res 63:2462–2469
Rampling R et al (2016) A cancer research UK first time in human phase I trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma. Clin Cancer Res: Off J Am Assoc Cancer Res 22:4776–4785. https://doi.org/10.1158/1078-0432.ccr-16-0506
Ransohoff RM, Engelhardt B (2012) The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 12:623–635
Reardon DA et al (2015) ReACT: overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. J Clin Oncol 33:2009–2009. https://doi.org/10.1200/jco.2015.33.15_suppl.2009
Reardon DA et al (2016) Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol Res 4:124–135. https://doi.org/10.1158/2326-6066.cir-15-0151
Reardon DA, Wucherpfennig K, Chiocca EA (2017) Immunotherapy for glioblastoma: on the sidelines or in the game? Discov Med 24:201–208
Reardon D et al. (2018) ATIM-23. ANTI-CD27 Agonist antibody varlilumab in combination with nivolumab for recurrent glioblastoma (rGBM): phase 2 clinical trial results. Neuro-Oncology 20:vi6–vi6. https://doi.org/10.1093/neuonc/noy148.018
Roth P, Valavanis A, Weller M (2017) Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab. Neuro Oncol 19:454–456. https://doi.org/10.1093/neuonc/now265
Sampson JH et al (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol: Off J Am Soc Clin Oncol 28:4722–4729. https://doi.org/10.1200/jco.2010.28.6963
Sampson JH et al (2011) Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 13:324–333. https://doi.org/10.1093/neuonc/noq157
Sampson JH et al (2015) Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143. J Clin Oncol 33:3010–3010. https://doi.org/10.1200/jco.2015.33.15_suppl.3010
Schumacher T et al. (2014) A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512:324–327. https://doi.org/10.1038/nature13387
Schuster J et al (2015) A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol 17:854–861. https://doi.org/10.1093/neuonc/nou348
Sharma P et al (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18:312–322. https://doi.org/10.1016/S1470-2045(17)30065-7
Sharpe AH, Pauken KE (2018) The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 18:153–167. https://doi.org/10.1038/nri.2017.108
Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330
Tawbi HA et al (2018) Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 379:722–730. https://doi.org/10.1056/NEJMoa1805453
Tawbi HA-H et al. (2019) Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204). J Clin Oncol 37:9501–9501. https://doi.org/10.1200/JCO.2019.37.15_suppl.9501
Tchirkov A et al (2003) Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas. Br J Cancer 88:516–520. https://doi.org/10.1038/sj.bjc.6600754
Weber JS et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375–384. https://doi.org/10.1016/S1470-2045(15)70076-8
Wei B, Wang L, Zhao X, Du C, Guo Y, Sun Z (2014) The upregulation of programmed death 1 on peripheral blood T cells of glioma is correlated with disease progression. Tumour Biol: J Int Soc Oncodevelopmental Biol Med 35:2923–2929. https://doi.org/10.1007/s13277-013-1376-9
Weller M et al (2014) Assessment and prognostic significance of the epidermal growth factor receptor VIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. Int J Cancer 134:2437–2447. https://doi.org/10.1002/ijc.28576
Weller M et al (2017) Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18:1373–1385. https://doi.org/10.1016/s1470-2045(17)30517-x
Westphal M et al (2013) Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol 14:823–833. https://doi.org/10.1016/s1470-2045(13)70274-2
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Medikonda, R., Pant, A., Lim, M. (2023). Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors. In: Rezaei, N., Hanaei, S. (eds) Human Brain and Spinal Cord Tumors: From Bench to Bedside. Volume 1. Advances in Experimental Medicine and Biology, vol 1394. Springer, Cham. https://doi.org/10.1007/978-3-031-14732-6_5
Download citation
DOI: https://doi.org/10.1007/978-3-031-14732-6_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-14731-9
Online ISBN: 978-3-031-14732-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)